COMPANY NEWS


Alembic Pharmaceuticals Ltd
BSE Code 533573 ISIN Demat INE901L01018 Book Value (₹) 264.28 NSE Symbol APLLTD Div & Yield % 1.07 Market Cap ( Cr.) 20,256.81 P/E * 41.44 EPS * 24.87 Face Value (₹) 2
* Profit to Earning Ratio
* Earning Per Share
Alembic Pharmaceuticals announces acquisition of Utility Therapeutics Back
(03 Jul 2025)
Alembic Pharmaceuticals Inc., wholly owned subsidiary of Alembic Pharmaceuticals has acquired Utility Therapeutics for a consideration of $12 million in staggered manner over period of time, depending on milestones achieved.

Utility Therapeutics is involved in the development and approval of two brand pharmaceutical products for the treatment of urinary tract infections (UTI).

-“Pivya” is an FDA approved product to treat uncomplicated UTIs in the US market.

-“MEC” is a product in development for treatment of the complicated UTIs in the US market.

As a product development company they have minimal turnover in last 3 years.